Organon Entered into a Research Collaboration and Exclusive License Agreement with Cirqle Biomedical for Non-hormonal Contraceptive Therapy
Shots:
- Cirqle to receive a $10M up front & is eligible to receive ~$360M in milestones along with royalties on net sales
- Organon to get an exclusive right globally to develop and commercialize the product while Cirqle will be responsible for conducting the preclinical studies based on the research collaboration
- The collaboration continues to expand the portfolio in women’s health to address patient unmet needs. The collaboration will use Organon’s deep expertise in women’s and reproductive health to bring new options for women who use contraception everywhere
Ref: Bussinesswire | Image: Organon
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
